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Background: Multinucleated giant cell-containing tumors and pseudotumors of bone represent a heterogeneous
group of benign and malignant lesions. Differential diagnosis can be challenging, particularly in instances of limited
sampling. The purpose of this study was to evaluate the contribution of the P63 in the positive and differential
diagnosis of giant cell tumor of bone.
Methods: This study includes 48 giant cell-containing tumors and pseudotumors of bone. P63 expression was
evaluated by immunohistochemistry. Data analysis was performed using Epi-info software and SPSS software
package (version 17).
Results: Immunohistochemical analysis showed a P63 nuclear expression in all giant cell tumors of bone, in 50% of
osteoid osteomas, 40% of aneurysmal bone cysts, 37.5% of osteoblastomas, 33.3% of chondromyxoide fibromas,
25% of non ossifiant fibromas and 8.3% of osteosarcomas. Only one case of chondroblastoma was included in this
series and expressed p63. No P63 immunoreactivity was detected in any of the cases of central giant cell
granulomas or langerhans cells histiocytosis. The sensitivity and negative predictive value (NPV) of P63
immunohistochemistry for the diagnosis of giant cell tumor of bone were 100%. The specificity and positive
predictive value (PPV) were 74.42% and 59.26% respectively.
Conclusions: This study found not only that GCTOB expresses the P63 but it also shows that this protein may serve
as a biomarker for the differential diagnosis between two morphologically similar lesions particularly in instances of
limited sampling. Indeed, P63 expression seems to differentiate between giant cell tumor of bone and central giant
cell granuloma since the latter does not express P63. Other benign and malignant giant cell-containing lesions
express P63, decreasing its specificity as a diagnostic marker, but a strong staining was seen, except a case of
chondroblastoma, only in giant cell tumor of bone. Clinical and radiological confrontation remains essential for an
accurate diagnosis.
Virtual slides: The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/
vs/1838562590777252.
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Figure 1 Histological findings of giant cell tumor of bone: the
tumor is composed of round mononuclear stromal cells and
uniformly scattered multinucleated giant cells, many of which
contain a large number of nuclei. Characteristically, the nuclei of
both stromal and giant cells are very similar. (hematoxylin-eosin
stain, original magnification × 200).
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Giant cell tumour of bone (GCTOB) is the prototype of
giant cell rich neoplasms of the skeleton. The term giant
cell tumour was coined by Bloodgood in 1912 [1] and it
was not until 1940 that Jaffe distinguished giant cell
tumour of bone from other bone tumours containing
many osteoclast-like giant cells [2]. This lesion repre-
sents 4% to 5% of all primary bone tumors and mainly
occurs in skeletally mature patients (peak incidence be-
tween ages 20 and 45 years) with a slight female pre-
dominance [3-5]. It most commonly arises at the
epiphyses of long bones like the distal femur, proximal
tibia, distal radius and proximal humerus [6]. This
tumor can be locally aggressive with a tendency for re-
currence. Lung metastases occur infrequently; more
rarely, this tumor behaves as a sarcoma [4,7]. Because ofFigure 2 Histological findings of aneurysmal bone cyst: the
tumor is composed of blood-filled cystic spaces lined by
fibrous septa that are composed of uniform fibroblasts and
multinucleated giant cells (hematoxylin-eosin stain, original
magnification × 200).its different evolution and prognosis, GCTOB must be
distinguished from other multinucleated giant cell-
containing tumors and pseudotumors. Differential diag-
nosis can be challenging, particularly in instances of
limited sampling such as with needle-core biopsies. It
is based not only on histology, but also on clinical and
radiological data. There is currently no well-accepted
diagnosis marker available for GCTOB, but recent
studies using immunohistochemistry and molecular
methods have demonstrated overexpression of p63 in the
stromal cells of most giant cell tumors of bone and advo-
cate its use as a diagnostic marker [3,4,6]. P63 was identi-
fied in 1998 [8]. It belongs to the family of transcription
factors that also includes p53 and p73 [9]. It is mostly
used as a diagnostic aid in breast, prostate, and salivary
gland cancer because of its high sensitivity and specificity
for mammary and salivary myoepithelial cells and pros-
tatic basal cells [3,10-12]. It can be a useful tool in distin-
guishing urothélial carcinoma from prostatic carcinoma
[13] and it can also be used as a prognosis factor as in
adenoid cystic carcinoma [14].
The purpose of this study is to determine whether
GCTOB expresses p63, and whether p63 can be used as
a biomarker to discriminate GCTOB from other giant
cell-rich tumors.
Methods
This study concerns 48 giant cell-containing tumors
and pseudotumors of bone that were retrieved from
department of pathology of Hassan II University Hos-
pital in Fez, from January 2009 to February 2012. They
include 12 osteosarcomas, 8 osteoblastomas, 5 GCTOB
(Figure 1), 5 aneurysmal bone cysts (ABCs) (Figure 2),
4 osteoid osteomas (OO), 4 central giant cell granu-
lomas (CGCGs) (Figure 3), 4 non ossifiant fibromasFigure 3 Histological findings of central giant cell granuloma:
the tumor consists of spindled fibroblasts admixed with
numerous multinucleated giant cells that tend to be arranged
in small clusters. They contain fewer nuclei than seen in giant cell
tumour of bone. Scattered lymphocytes are present (hematoxylin-
eosin stain, original magnification × 200).
Table 1 Demographic data and location of tumours
Case number Diagnosis Age Sex Location
1 osteosarcoma 34 F femur
2 osteosarcoma 40 F femur
3 osteosarcoma 19 M femur
4 osteosarcoma 19 M femur
5 osteosarcoma 12 F femur
6 osteosarcoma 14 F femur
7 osteosarcoma 23 M humerus
8 osteosarcoma 21 F humerus
9 osteosarcoma 20 M humerus
10 osteosarcoma 25 M Tibia
11 osteosarcoma 18 F Tibia
12 osteosarcoma 27 M mandible
13 osteoblastoma 14 M femur
14 osteoblastoma 19 F femur
15 osteoblastoma 20 F radius
16 osteoblastoma 25 F Cuneiform bone
17 osteoblastoma 23 M 5th metatarsal bone
18 osteoblastoma 23 M astragal
19 osteoblastoma 21 M mandible
20 osteoblastoma 57 M vertebrae
21 GCTOB 29 F femur
22 GCTOB 30 M femur
23 GCTOB 21 F 5th metacarpal bone
24 GCTOB 21 F Fibula
25 GCTOB 40 F Tibia
26 ABC 19 F Fibula
27 ABC 14 F Fibula
28 ABC 16 M Femur
29 ABC 13 F Tibia
30 ABC 15 M 1st metatarsal bone
31 OO 30 F femur
32 OO 28 M femur
33 OO 24 M astragal
34 OO 24 M Fibula
35 CGCG 9 M mandible
36 CGCG 15 M mandible
37 CGCG 48 F Maxilla
38 CGCG 53 F Maxilla
39 NOF 16 F Tibia
40 NOF 19 M Tibia
41 NOF 16 F Tibia
42 NOF 8 M femur
43 CMF 23 M Toe
44 CMF 33 M Tibia
Table 1 Demographic data and location of tumours
(Continued)
45 CMF 59 F Sphenoid bone
46 FD 19 M Femur
47 chondroblastoma 23 M calcaneus
48 LCH 7 M Ilium
M: male; F: female.
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dysplasia (FD), 1 chondroblastoma and 1 Langerhans
cell histiocytosis (LCH). The data were collected pro-
spectively from pathology reports, from forms filled by
trauma surgeons, pediatric surgeons and otorhinolaryn-
gologists, and from radiographs. A form was filled for
each patient, including the following informations:
patient’s name, age, sex, tumor location, histological
type and P63 expression. The demographic data and
location of these cases are shown in Table 1.
All specimens were fixed in 10% buffered formalin,
embedded in paraffin and 4 micron-thick sections were
stained with hematoxylin and eosin for routine histo-
logical examination.Immunohistochemical staining
P63 expression was evaluated by immunohistochemis-
try. All immunohistochemical stains were performed
on a Ventana Benchmark LT automated immunostai-
ner, on 3 micron-thick sections that were incubated
with a mouse monoclonal antibody against p63 (clones
463M-17, prediluated, ready to use, Cell Marque
Datasheet).
The stained slides were examined without knowing
the original histologic diagnosis. As there is no consen-
sual scoring, we evaluated intensity of staining as weak
(1+), moderate (2+), and strong (3+), and percentage of
staining cells. A case was considered positive when nu-
clear staining of a single lesional cell or more was found.Statistical analysis
The calculation of average age, median age, sex ratio and
rate of P63 expression was done using Epi-info software.
Sensitivity, specificity, positive predictive value (PPV)
and negative predictive value (NPV) were calculated in
the GCTOB vs. not GCTOB and P63 positive vs. P63
negative groups using the SPSS software package (ver-
sion 17).Results
The patients’ age ranged between 7 and 59 years with an
average of 23.8 years and a median of 21 years. A
discrete male predominance was noted (sex ratio = 1.2).
Figure 6 Immunohistochemical findings of CGCG: negative
nuclear staining with P63 in mononuclear cells (original
magnification × 100).
Figure 4 Immunohistochemical findings of GCTOB: strong
nuclear staining with P63 in mononuclear cells (original
magnification × 100).
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expression in all GCTOB (Figure 4), 2 of 4 osteoid
osteomas (50%), 2 of 5 ABCs (40%) (Figure 5), 3 of 8
osteoblastomas (37.5%), 1 of 3 CMFs (33.3%), 1 of 4
NOFs (25%), 1 of 12 osteosarcomas (8.3%) and in the
single case of chondroblastoma included in this series.
The staining was observed only in the nucleus of the
mononuclear cells and no staining was present in the
multinucleated giant cells. No P63 immunoreactivity was
detected in any of the cases of CGCG (Figure 6), LCH,
and FD. Strong staining was seen in 40% of GCTOB (2
cases) and in one case of osteoblastomas (33.3% of P63
positive osteoblastomas). Moderate staining was seen in
2 cases of GCTOBs (40%) and in one case of ABCs. In
other tumors expressing P63, staining intensity was
weak. Staining was seen in 30%-60% of tumor cells in
GCTOB and in 20% and 50% of tumor cells in ABCs. In
other tumors, percentage of reactive cells was lower
(5%-30% in osteoblastomas, 10% in osteoid osteomas,
osteosarcomas and CMFs, and 5% in chondroblastoma
and NOFs).Figure 5 Immunohistochemical findings of ABC: moderate and
focal nuclear staining with P63 in mononuclear cells (original
magnification × 100).The sensitivity and negative predictive value (NPV) of
P63 immunohistochemistry for the diagnosis of GCTOB
were 100%. The specificity and positive predictive value
(PPV) were 74.42% and 59.26% respectively.
Discussion
In this study, we showed that all GCTOBs express P63.
Dickson [4] and Linden [15] found similar results by
immunohistochemistry. They reported P63 overexpres-
sion in all GCTOB. In De la Rosa’s study [3], P63 immu-
noreactivity was seen in 20 of 23 GCTOBs (86.9%).
Similar results were reported by Lee [6] who showed a
P63 overexpression by immunohistochemistry in 81% of
cases (n=26) with a strong staining in 69% (Table 2).
The immunostaining was mostly confined to the mono-
nuclear component [3,4,6]. This strong expression of
P63 suggests that this protein may be implicated in the
pathogenesis of GCTOB but determining its exact role
requires further investigation.
The relationship of GCTOB and central giant cell
granuloma has long been controversial. The absence of
p63 expression in CGCG suggests that these tumors
may have a pathogenesis that differs from that of
GCTOB. P63 negativity found in all cases of CGCG in
our study is consistent with results obtained by Dickson
[4] and Lee [6] who found negativity in all cases (n=12
in each series). De la Rosa [3] showed different results
with p63 positivity in all cases (n = 4) (Table 2).
Only one case (8.3%) of osteosarcomas included in our
study showed overexpression of P63. Proportion of
immunoreactive cells was less than 10% and staining
was 1+ in intensity. The rate of P63 expression in other
series remains low (2 cases/13 in Lee’s study, with low
intensity [6], and 2 cases/4 in De la Rosa’s study [3])
(Table 2).
In this work, we recorded a single case of chondro-
blastoma. The immunohistochemical study showed P63
Table 2 P63 expression of in current series and in other published series
Diagnosis Our series Dickson’s series [4] De la Rosa’s series [3] Lee’s series [6]
N° of cases P63+ cases (%) N° of cases P63+ cases (%) N° of cases P63+ cases (%) N° of cases P63+ cases (%)
GCTOB 5 100% 17 100% 23 86.9% 6 81%
Osteosarcoma 12 8.3% 0 - 4 50% 13 15.3%
Osteoblastoma 8 37.5% 0 - 0 - 0 -
ABC 5 40% 7 28.6% 8 62.5% 25 20%
CGCG 4 0% 12 0% 4 100% 12 0%
NOF 4 25% 0 - 6 16.6% 0 -
OO 4 50% 0 - 0 - 0 -
CMF 3 33.4% 0 - 0 - 12 0%
Chondroblastoma 1 100% 10 30% 12 83.3% 15 40%
FD 1 0% 0 - 2 0% 4 0%
LCH 1 0% 0 - 0 - 0 -
chondrosarcoma 0 - 0 - 0 - 0 -
Brown tumor 0 - 0 - 0 - 4 0%
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tensity. The rate of expression in other studies is va-
riable. In Dickson’s study, 3 of 10 chondroblastomas
expressed p63 (30.0%); this ranged from 7–75% of cells,
and staining was predominantly mild-moderate in inten-
sity [4]. De Larosa found a higher expression (83.3%, 10
of 12 chondroblastomas) with moderate staining in 6
cases, weak staining in 3 cases and strong staining in
only one case [3]. Lee showed P63 staining in 40% of
cases (6 of 15). To differentiate between chondroblas-
toma expressing P63 and GCTOB, he used PS100: chon-
droblastoma shows positive S-100 immunostaining
whereas only occasional weak S-100 immunostaining is
seen in GCTOB [6]. In the same study, no P63 staining
was seen in chondromyxoïd fibromas (n=12) (Table 2).
The rate of P63 expression in ABC in Dickson’s [4]
and Lee’s [6] studies is lower than that obtained in our
study: 28.6% (2 cases/7) and 20% (5cases/25) respec-
tively. De la Rosa [3] and Linden [15] found higher
results: 62.5% and 100% respectively (Table 2). If some
cases of ABC are P63 +, they could be a component of a
GCTOB.
In fibrous dysplasia, our results are concordant with
those found by De La Rosa [3] (two cases all negative)
and Lee (4 cases all negative) [6]. Non ossifiant fibroma
showed P63 expression in one case with weak and focal
staining. De la Rosa found similar results with P63 ex-
pression in 1 of 6 cases (16.6%) (Table 2). Proportion of
positive cells was less than 10% and staining intensity
was weak [3].
In current study, 50% of osteoid osteomas and 37.5%
of osteoblastomas expressed P63. LCH showed no P63
immunostaining. These tumors were not included in the
other studies.P63 contribution in the differential diagnosis between
GCTOB and other multinucleated giant cell-containing
lesions of bone is variable. Dickson [4] considers that
P63 can be useful as a biomarker for the differential
diagnosis between GCTOB and other lesions particularly
central giant cell granuloma, since these do not express
P63. De La Rosa [3] found a high P63 negative predictive
value (91.17%) but a low specificity (53.36%) which limits
the use of this protein as an immunohistochemical mar-
ker for differential diagnosis. Lee [6] considers that the
use of P63 can help in histological diagnosis of GCTOB.
In current study, the P63 negative predictive value is
100%, this means that in difficult cases, P63 negativity can
eliminate a GCTOB. The positive predictive value is low
(59.26%). However, except a case of osteoblastoma, a
strong staining was found only in GCTOB. Therefore, it
is strongly suggestive of this tumor.Conclusion
This study shows that P63 may serve as a biomarker for
the differential diagnosis between GCTOB and other
morphologically similar lesions, particularly CGCG since
the latter does not express P63. Other giant cell-
containing lesions express P63, decreasing its specificity
as a diagnostic marker, but a strong staining was seen,
except a case of chondroblastoma, only in GCTOB.
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